A Promising New Drug for Treating Cognitive Decline in Schizophrenia
The Science Behind is playing a crucial role in the neurophysiological screening and monitoring of a phase I clinical trial for a new drug, MDI-26478,…
Read moreEvent: 6th Annual Neuroscience R&D Conference
We’re excited to announce that we will be exhibiting at the 6th MarketsandMarkets Neuroscience R&D Conference – 9th – 10th October 2023 The 6th Annual…
Read moreThe Science Behind Supports Rare Disease Day
Rare Disease Day is an important annual observance that raises awareness about rare diseases and their impact on patients’ lives. First established in 2008 by…
Read moreRecognised as Best in Early Phase Neuroscience Clinical Trials
Recognised as the Best in Early Phase Neuroscience Clinical Trials: Our Company Wins European Enterprise Award. Exciting news! Our company has been awarded the…
Read moreRevolutionising Drug Development: The Power of TMS-EEG in First-in-Human Clinical Trials
Pharmaceutical companies are constantly searching for new and innovative ways to test the safety and efficacy of their drugs, and one promising method, TMS-EEG, is the…
Read moreEvent: Biomarkers UK 2022
Visit us at Biomarkers UK 2022 The Science Behind is pleased to announce that we will be attending Biomarkers UK 2022 in-person conference this Spring….
Read moreWebinar announcement: Embedding neuroscience for target engagement in FIH clinical trials
The Science Behind and contract research organisation Simbec-Orion are jointly hosting a free webinar on Wednesday 19th January on Embedding Neuroscience Techniques to Measure Target…
Read moreTwo ISO Standards awarded to The Science Behind
We are delighted to announce that The Science Behind has achieved certification for ISO9001:2015 for Quality Management Systems and ISO27001:2017 for Information Security Management Systems….
Read more